CompanyGraph
Tianjin Lisheng Pharmaceutical Co., Ltd.
002393 · SZSE · China
lishengpharma.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $40.19M, above the global median of $16.24M
- FinancialsAltman Z-Score 4.46: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.14%Above 5Y avg (1.79%)
Annual Rate
CNY 0.60Paid annual
Payout Ratio
40.4%Sustainable
Payback Period
24.0 yr
Last Ex-Dividend
Apr 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.53BCNY671.62M · vs all stocks (USD)
Trailing P/E
11.04xRevenue (TTM)
1.35BCNY200.87M · vs all stocks (USD)
Profit Margin
30.48%Beta
-0.0660xvs all stocks
52-Week Change
-33.51%vs all stocks
Market Capitalization
4.53BCNY671.62M · vs all stocks (USD)
Enterprise Value
2.23BCNY331.13M · vs all stocks (USD)
Trailing P/E
11.04xPrice to Sales (TTM)
3.37xPrice to Book (MRQ)
1.00xEnterprise to Revenue
1.65xEnterprise to EBITDA
12.32xGross Margin
55.32%Profit Margin
30.48%Operating Margin
15.46%Return on Assets (TTM)
1.20%Return on Equity (TTM)
8.85%Revenue (TTM)
1.35BCNY200.87M · vs all stocks (USD)
Revenue per Share (TTM)
4.41CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-10.20%Gross Profit (TTM)
716.32MCNY106.23M · vs all stocks (USD)
EBITDA (TTM)
506.59MCNY75.13M · vs all stocks (USD)
Net Income (TTM)
412.89MCNY61.23M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.10%Operating Cash Flow (TTM)
249.46MCNY37.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
271.03MCNY40.19M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
4.14%vs all stocks
5-Year Average Dividend Yield
1.79%vs all stocks
Payout Ratio
40.37%Minority Interest (Equity)
32.49MCNYFY2025 · Dec 31, 2025Revenue
1.39BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
622.79MCNYFY2025 · Dec 31, 2025Gross Profit
769.23MCNYFY2025 · Dec 31, 2025Operating Income
112.58MCNY16.70M · vs all stocks (USD)
Pre-tax Income
455.61MCNYFY2025 · Dec 31, 2025Income Tax Expense
32.88MCNYFY2025 · Dec 31, 2025Net Income
422.73MCNYFY2025 · Dec 31, 2025EBIT
457.86MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
554.16MCNYFY2025 · Dec 31, 2025Research & Development
115.19MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
302.50MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
51.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.25MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.35CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.35CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
308.36MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
308.36MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
422.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-6.44MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
489.61MCNYFY2025 · Dec 31, 2025Free Cash Flow
455.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.54BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
422.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.92MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
78.87MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-34.53MCNYFY2025 · Dec 31, 2025Net Acquisitions
-6.99MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.44BCNYFY2025 · Dec 31, 2025Sale of Investments
3.31BCNYFY2025 · Dec 31, 2025Other Investing Activity
-12.50KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-167.29MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
24.31MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-39.75MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-97.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-138.14MCNYFY2025 · Dec 31, 2025Shares Outstanding
309.14MSharesUpdated Aug 19, 2026Float Shares
146.26MSharesUpdated Aug 19, 2026% Held by Insiders
54.89%vs all stocks
% Held by Institutions
0.51%vs all stocks
Total Cash (MRQ)
2.48BCNY368.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.97CNYUpdated Aug 19, 2026Total Debt (MRQ)
43.93MCNY6.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0095xCurrent Ratio (MRQ)
4.52xBook Value per Share (MRQ)
14.80CNYUpdated Aug 19, 2026Total Assets
5.58BCNY828.17M · vs all stocks (USD)
Total Current Assets
3.33BCNYFY2025 · Dec 31, 2025Total Liabilities
923.86MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.25BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
162.13MCNYFY2025 · Dec 31, 2025Total Current Liabilities
761.73MCNYFY2025 · Dec 31, 2025Cash
1.54BCNYFY2025 · Dec 31, 2025Cash Equivalents
778.10KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.54BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
255.04MCNYFY2025 · Dec 31, 2025Inventory
215.11MCNYFY2025 · Dec 31, 2025Accounts Payable
130.57MCNYFY2025 · Dec 31, 2025Short-term Debt
40.96MCNYFY2025 · Dec 31, 2025Other Current Liabilities
13.71MCNYFY2025 · Dec 31, 2025Long-term Debt
4.54MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.87MCNYFY2025 · Dec 31, 2025Common Stock (Book)
257.59MCNYFY2025 · Dec 31, 2025Retained Earnings
1.77BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.66BCNY691.16M · vs all stocks (USD)
Treasury Stock
85.77MCNYFY2025 · Dec 31, 202552-Week Low
13.37CNYUpdated Aug 19, 202652-Week High
22.25CNYUpdated Aug 19, 202652-Week Change
-33.51%vs all stocks
Beta
-0.0660xvs all stocks
50-Day MA
14.48CNYUpdated Aug 19, 2026200-Day MA
16.96CNYUpdated Aug 19, 2026Avg 10-Day Volume
3.03MSharesUpdated Aug 19, 2026Avg 30-Day Volume
3.55MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.34CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.46: safe zoneNotable
Altman Z-Score: 4.46
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $40.19M, above the global median of $16.24MNotable
Levered free cash flow (USD): 40,193,732.39Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Pharma Research Products Co., Ltd
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Medlive Technology Co. Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth